Series B · Biotech
Crystalys Therapeutics: Series B
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
Funding history
Series B · This round$130M
Loading rounds…
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout